Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/Oncologymhn linvoseltamab-gcpt Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedmhnPolicy CP.PHAR.743

    Linvoseltamab-gcpt (Lynozyfic) for relapsed/refractory multiple myeloma

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.743 alerts

    Get alerted when Policy CP.PHAR.743 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, dosing limits, and coverage criteria for Linvoseltamab-gcpt (Lynozyfic) in adult patients with relapsed or refractory multiple myeloma across commercial, HIM, and Medicaid lines of business.

    Policy Summary
    Payermhn
    PolicyLinvoseltamab-gcpt (Lynozyfic) for relapsed/refractory multiple myeloma
    Policy CodePolicy CP.PHAR.743
    Change TypeHCPCS code update (J9601 added)
    Effective DateOct 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation of diagnosis, specialist involvement, age, relapsed/refractory status, measurable disease or IMWG-defined progression, and prior receipt or intolerance of ≥4 prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 antibody.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS J9601 (linvoseltamab-gcpt) was added and previous temporary codes removed/updated in the coding section.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥4prior lines required
    ≥18minimum age
    6 moinitial approval duration
    2boxed warnings
    step-up→weekly→biweeklydosing cadence

    Coverage Criteria for Linvoseltamab-gcpt (Lynozyfic)

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Initial Approval - Multiple Myeloma: 1. Diagnosis of multiple myeloma (MM). 2. Prescribed by or in consultation with an oncologist or hematologist. 3. Age ≥ 18 years. 4. Disease is relapsed or refractory. 5. One of the following: (a) Measurable disease within the last 28 days as evidenced by any of: (i) serum M-protein ≥ 0.5 g/dL; (ii) urine M-protein ≥ 200 mg/24 h; (iii) involved serum free light chain (FLC) ≥ 10 mg/dL with abnormal kappa:lambda ratio; OR (b) Progressive disease per IMWG response criteria assessed within 60 days following the last dose of the last anti-myeloma regimen. 6. Member has received or has documented intolerance to ≥ 4 prior lines of therapy that include: (a) a proteasome inhibitor; (b) an immunomodulatory agent; and (c) an anti‑CD38 monoclonal antibody. 7. No known multiple myeloma brain lesions or meningeal involvement. 8. Requested dose does not exceed the specified dosing schedule (step-up and maintenance) OR the requested dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence). 9. Prescribed regimen must be FDA‑approved or recommended by NCCN.≥4 prior lines

    Dosing schedule specifics: Day 1: 5 mg; Day 8: 25 mg; Day 15: 200 mg; weekly 200 mg from week 4–13; week 14 onward 200 mg every 2 weeks (see policy).

    Continuation Therapy — Covered when ALL of the following are met

    Continuation therapy covered when ALL of the following are met

    Continued Therapy - Multiple Myeloma: 1. Member is currently receiving Lynozyfic via the Centene benefit, or documentation shows the member has received Lynozyfic for at least 30 days for a covered indication. 2. Member is responding positively to therapy. 3. If a dose increase is requested, one of the following must be met: (a) New dose does not exceed: (i) 200 mg every 2 weeks; OR (ii) 200 mg every 4 weeks for members who have achieved and maintained very good partial response (VGPR) or better at or after week 24 and have received at least 17 doses of 200 mg; OR (b) New dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence). 4. Prescribed regimen must be FDA‑approved or recommended by NCCN.see node text

    Approval duration: Medicaid/HIM 12 months; Commercial 6 months or to member renewal date, whichever is longer.

    Dosing and administration — Dosing/admin must follow prescribing schedule and product availability

    Covered when dosing and administration follow the prescribing schedule and product availability

    Dosing sequence: Patient receives step-up dosing: Day 1: 5 mg IV; Day 8: 25 mg IV; Day 15: 200 mg IV (first treatment dose). Weekly dosing: Week 4 to Week 13 — 200 mg IV once weekly (10 doses). Maintenance/biweekly dosing: Week 14 and every 2 weeks thereafter — 200 mg IV every 2 weeks. For patients who have achieved and maintained VGPR or better at or after week 24 and received at least 17 doses of 200 mg, maintenance may be 200 mg IV every 4 weeks.

    Product availability: single-dose vials 5 mg and 200 mg.

    Requests for indications that are not FDA‑approved and are not specifically addressed by this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or other governing evidence of coverage documents.

    Use of linvoseltamab-gcpt in patients with known multiple myeloma brain lesions or meningeal involvement is not supported by the pivotal LINKER‑MM1 trial, as these populations were expressly excluded from that study.

    Linvoseltamab-gcpt carries boxed warnings for cytokine release syndrome and neurologic toxicity, including immune effector cell‑associated neurotoxicity syndrome (ICANS). Use without appropriate monitoring and institution of recommended mitigation strategies for these risks is considered inappropriate.

    Approved Induction and Maintenance Regimens

    RegimenDose / ScheduleCoverage
    FDA‑approved induction and maintenance regimen for relapsed/refractory multiple myeloma
    Day 1 (Step‑up 1): 5 mg IV; Day 8 (Step‑up 2): 25 mg IV; Day 15 (first treatment dose): 200 mg IV; One week after Day 15 and Weeks 4–13: 200 mg IV once weekly (10 weekly doses); Week 14 and every 2 weeks thereafter: 200 mg IV every 2 weeks
    Prescribed regimen must be FDA‑approved or recommended by NCCN; requests exceeding schedule must be supported by guidelines/literature
    ConditionMaintenance Dosing OptionCoverage
    Standard responders (no sustained VGPR after specified dosing)
    200 mg IV every 2 weeks
    Maintenance dosing limited to 200 mg every 2 weeks unless criteria for every‑4‑week dosing are met
    PhaseSchedule summaryNotes / Coverage
    Biweekly (maintenance)
    Week 14 and every 2 weeks thereafter: 200 mg IV every 2 weeks
    Alternate every‑4‑week maintenance (200 mg every 4 weeks) allowed only for patients with sustained VGPR or better at/after week 24 who have received ≥17 doses of 200 mg

    Line of Therapy and Prior Treatment Requirements

    salvage

    Line of therapy requirement: Relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.≥4 prior lines

    Indication per FDA-approved labeling.

    salvage

    Reference to evidence and compendia: LINKER-MM1 pivotal study and NCCN compendium are referenced for indication and use; these sources support the accelerated approval and clinical context for use in relapsed/refractory MM.

    See full policy references for citations.

    Provider Actions — Authorization, Documentation, and Billing

    Prior Authorization

    Prior Authorization Required

    Prior authorization required. Provider must document diagnosis, specialist involvement, patient age, relapsed/refractory status, measurable disease or progressive disease per IMWG, prior lines of therapy, and that step‑up and maintenance dosing follows the approved regimen or is supported by guideline/literature for off‑label use.

    • Submit office chart notes, relevant lab results (e.g., serum/urine M‑protein, serum free light chain), and documentation of prior therapies including intolerance or resistance.
    • Prescriber should be an oncologist or hematologist or request must include consultation note.
    Documentation Required

    Required Clinical Documentation

    Requests lacking required clinical documentation are at risk of denial. Include supporting evidence that the member meets all approval criteria (diagnosis, measurable disease or IMWG‑defined progressive disease, prior lines of therapy).

    Coding and Billing

    HCPCS CodesHCPCS
    J9601Injection, linvoseltamab-gcpt, 1 mg
    J9999Not otherwise classified, antineoplastic drugs
    inv-08: Step-up dosing schedule
    Step-up dosing scheduleDay 1: 5 mg IV (Step-up dose 1); Day 8: 25 mg IV (Step-up dose 2); Day 15: 200 mg IV (first treatment dose)
    Weekly induction dosingWeek 4 to Week 13: 200 mg IV once weekly (one week after Day 15 treatment dose)
    Biweekly maintenance dosingWeek 14 and every 2 weeks thereafter: 200 mg IV every 2 weeks

    Background

    Linvoseltamab-gcpt (Lynozyfic) is a bispecific BCMA‑directed CD3 T‑cell engager indicated under accelerated approval for adult patients with relapsed or refractory multiple myeloma who have received prior therapies. The policy references the LINKER‑MM1 pivotal trial and notes trial exclusions and IMWG response criteria used to define progressive disease.

    Definitions and Abbreviations

    inv-19: BCMA — B-cell maturation antigen
    Acronym definitionBCMA = B-cell maturation antigen
    ContextBCMA is listed in the policy Appendix A abbreviation/acronym key
    Clinical relevanceBCMA is the target of linvoseltamab-gcpt (a BCMA-directed CD3 T-cell engager)
    inv-20: IMWG — International Myeloma Working Group
    Acronym definitionIMWG = International Myeloma Working Group
    Usage in policyIMWG response criteria are referenced for documenting progressive disease and response
    Source
    Policy Summary
    Payermhn
    PolicyLinvoseltamab-gcpt (Lynozyfic) for relapsed/refractory multiple myeloma
    Policy CodePolicy CP.PHAR.743
    Change TypeHCPCS code update (J9601 added)
    Effective DateOct 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation of diagnosis, specialist involvement, age, relapsed/refractory status, measurable disease or IMWG-defined progression, and prior receipt or intolerance of ≥4 prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 antibody.
    SourceLink
    On This Page
    Coverage Criteria for Linvoseltamab-gcpt (Lynozyfic)Approved Induction and Maintenance RegimensLine of Therapy and Prior Treatment RequirementsProvider Actions — Authorization, Documentation, and BillingCoding and BillingBackgroundDefinitions and Abbreviations
  1. Provide documentation of measurable disease within 28 days OR documentation of progressive disease per IMWG within 60 days following last dose of prior regimen.
  2. Document prior receipt of ≥4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 antibody.
  3. Non‑FDA indications require evidence per off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) or may be denied.
  4. Step Therapy

    Specify Step‑up and Maintenance Dosing

    Step‑up and maintenance dosing regimen must be specified on the authorization request. Requests exceeding the dosing schedule or missing step‑up/maintenance plans may be denied unless supported by practice guidelines or peer‑reviewed literature.

    • Required step‑up dosing: Day 1 = 5 mg; Day 8 = 25 mg; Day 15 = 200 mg.
    • Weekly dosing: Week 4–13 = 200 mg IV once weekly (10 doses). Maintenance dosing: Week 14 onward = 200 mg every 2 weeks; patients with VGPR or better at/after Week 24 and ≥17 doses of 200 mg may move to 200 mg every 4 weeks.
    • If dosing differs for off‑label use, prescriber must submit supporting guideline or peer‑reviewed evidence.
    Billing Rule

    Coding and Claim Submission

    Billing and coding must use current HCPCS codes. Incorrect, outdated, or inappropriate code selection may result in claim denials or delays.

    • Use HCPCS J9601 (injection, linvoseltamab‑gcpt, 1 mg) when applicable.
    • If J9601 is not applicable, use J9999 only with appropriate supporting documentation and payer guidance.
    • Providers should verify coding guidance prior to claim submission and update codes if changes occur.
    Defined in Appendix A abbreviation/acronym key
    inv-21: VGPR — Very good partial response
    Acronym definitionVGPR = Very good partial response
    Role in dosingPatients who achieve and maintain VGPR or better at/after week 24 and received ≥17 doses of 200 mg may switch maintenance to 200 mg every 4 weeks
    Location in policyDefined in Appendix A abbreviation/acronym key
    inv-22: IMWG progressive disease — IMWG definition includes >=25% increase from nadir etc.
    IMWG progressive disease definitionAn increase of ≥25% from the lowest response value in any of: serum M‑component (absolute increase ≥0.5 g/dL), urine M‑component (absolute increase ≥200 mg/24 h), involved‑uninvolved FLC difference (absolute increase >10 mg/dL) in patients without measurable serum/urine M‑protein, or bone marrow plasma cell percentage (absolute increase ≥10%) in patients without measurable disease by M‑protein or FLC.
    Threshold detailOnly one of the listed criteria is required to define progressive disease per IMWG
    Policy useProviders should document disease status using IMWG response criteria when supporting progression for authorization requests